Amendment 0003 Bicalutamide 50MG & 500MG tablets
ID: SPE2D2-24-R-0016Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/ef25bac4ece746f083c191608f3ae528/view
Timeline
    Description

    The Defense Logistics Agency (DLA) is soliciting proposals for a national requirements contract for Bicalutamide 50MG tablets, available in 30-count and 500-count bottles. The procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for various Department of Defense and other federal health programs. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base period and four one-year options, with an estimated annual quantity of 23,529 for the 30-count and 1,961 for the 500-count bottles. Interested parties should submit their proposals by February 7, 2025, at 3:00 PM, and can direct inquiries to Keith Ryales at keith.ryales@dla.mil or by phone at 215-737-9199.

    Point(s) of Contact
    Keith Ryales
    (215) 737-9199
    keith.ryales@dla.mil
    Files
    Title
    Posted
    SF30_SPE2D224R00160002.pdf
    This government document pertains to the amendment of a solicitation for a contract involving pharmaceutical supplies, specifically Bicalutamide tablets. The amendment, designated as SPE2D2-24-R-0016, extends the solicitation's closing date to February 7, 2025, at 3:00 PM. It supersedes a previous amendment, labeled 0001, which has been declared null and void. The main focus requires contractors to provide current and previous commercial prices as well as federal supply schedule prices for two specific line items of Bicalutamide tablets in 30-count and 500-count bottles, excluding Federal Excise Tax. The document emphasizes that other terms and conditions of the original solicitation remain unchanged. Instructions for acknowledging receipt of the amendment and additional requirements for submitting offers are also outlined. Overall, it reflects the government's structured approach to modifying existing contracts and maintaining transparency in procurement processes related to medical supplies.
    SF30_SPE2D224R00160003.pdf
    This document is an amendment to a federal solicitation/modification of a contract, referenced as SPE2D2-24-R-0016. It primarily addresses changes regarding the solicitation's closing date, now set for February 14, 2025, at 3:00 PM. It also allows offers to be submitted via email to specified personnel due to a systemic issue. The amendment serves to modify existing contract terms while ensuring that all other stipulations from the original solicitation remain unchanged. Instructions for acknowledgment of the amendment are provided, stipulating that failure to acknowledge may result in the rejection of offers. Overall, this amendment facilitates the ongoing solicitation process by providing clarity on submission methods and deadlines, thus supporting contractor participation in the bidding process.
    SPE2D2-24-R-0016 (Bicalutamide) SF1449 w-attachment.pdf
    The document pertains to an official solicitation for commercial items issued by DLA Troop Support Medical Supply Chain. It includes essential details regarding the request for proposal (RFP) number SPE2D2-24-R-0016, with an offer due date of January 24, 2025. The RFP is unrestricted or set aside for various small business categories including service-disabled veteran-owned, women-owned, and HUBZone businesses. Contractors are required to complete specific blocks in the document to comply with terms and conditions, ensuring they deliver agreed-upon items. Additionally, it references Federal Acquisition Regulation (FAR) clauses applicable to the solicitation. The document also notes the need for signed acceptance by both the contractor and contracting officer, along with details for invoice submission and payment processing. Attached to the document is additional information concerning the specific item being solicited—Bicalutamide. This RFP underscores the federal government's structured procurement process and encourages participation from diverse businesses to fulfill its contracting needs efficiently.
    Lifecycle
    Title
    Type
    Bicalutamide 50MG tablets
    Currently viewing
    Solicitation
    Bicalutamide 50MG tablets
    Presolicitation
    Similar Opportunities
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Lansoprazole Capsules
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Lansoprazole capsules, specifically 30MG in 100 count bottles. This procurement aims to establish a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, ensuring a reliable supply of this essential pharmaceutical item. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, with the solicitation expected to be posted in April 2024. Interested parties should direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or 215-737-6031, and are encouraged to set up automated notifications for updates on the solicitation through the DLA Bid Board System and Sam.Gov.
    Telmisartan Tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Telmisartan Tablets, a pharmaceutical product, to be delivered over multiple contract years. This solicitation, identified as SPE2D2-24-R-0015, requires compliance with various federal regulations, including the submission of a Subcontracting Plan for large businesses and adherence to Federal Acquisition Regulation (FAR) clauses concerning ethics and subcontracting practices. Telmisartan is crucial for managing hypertension and ensuring a reliable pharmaceutical supply is vital for military personnel's health. Interested vendors should submit their electronic proposals via the Defense Logistics Agency Internet Bid Board System (DIBBS) and can contact Courtney Hunter-Stangler at 215-737-6845 or via email at Courtney.Hunter-Stangler@dla.mil for further information.
    Doxycycline Hyclate Solicitation
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Doxycycline Hyclate tablets under solicitation number SPE2D2-25-R-0004. This procurement aims to secure pharmaceutical products in various quantities and packaging configurations, with a focus on compliance with federal regulations and quality control measures. Doxycycline Hyclate is a critical antibiotic used in various medical applications, making this procurement essential for maintaining adequate supplies for military and healthcare operations. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by February 5, 2025, and are encouraged to contact Courtney Hunter-Stangler or Jason C. Wray for further information regarding the solicitation.
    Pantoprazole DR Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Metformin HCL
    Buyer not available
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Famotidine
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Valsartan
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    Repaglinide
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.